ライフサイエンスコーパス: antibody

1 te is required to develop a more efficacious antibody.

2 tralizing virus when expressed as monoclonal antibodies.

3 , for assessing the stability of therapeutic antibodies.

4 clusters closely associated with SARS-CoV-2 antibodies.

5 ctionalization with specific anti-PARK7/DJ-1 antibodies.

6 uring viral growth in the presence of single antibodies.

7 by a fast rise in serum IgG and neutralizing antibodies.

8 o difference in the presence of neutralizing antibodies.

9 e overcome using PD-L1 or PD-1 immunotherapy antibodies.

10 f Brazil and exhibit nonpathogenic anti-DSG1 antibodies.

11 s of secreted proteins such as cytokines and antibodies.

12 with cell-surface receptors and neutralising antibodies.

13 mline sequences, to HIV broadly neutralizing antibodies.

14 viously emerged as a target for neutralizing antibodies.

15 es in the presence of specific IgG biomarker antibodies.

16 on in mouse for brain parenchyma penetrating antibodies.

17 nitial screen for all therapeutic monoclonal antibodies.

18 oV-2 antibodies, compared with those without antibodies (93.4% versus 78.7%, p < 0.001), whereas tast

19 sign is complicated by concern that elicited antibodies (Abs) may cross-react with other flaviviruses

20 coincident with the development of antidrug antibodies (ADAs) against each of the DART molecules.

21 Most importantly, a significantly higher antibody affinity to RSV G was observed in nasal washes

22 r-protocol set developed clade C Env binding antibodies after the second vaccination, with higher tot

23 The patient was found to have anti-retinal antibodies against carbonic anhydrase II and enolase pro

24 e feasibility of isolating recombinant phage-antibodies against gluten from a non-immunized library o

25 While the therapeutic benefit of monoclonal antibodies against infectious disease agents may be deba

26 Neurological disorders with IgG antibodies against myelin-oligodendrocyte glycoprotein (

27 r than 10% of the US adult population formed antibodies against SARS-CoV-2, and fewer than 10% of tho

28 ted two fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome cor

29 by identification of immunoglobulin G (IgG) antibodies against T. gondii embryogenesis-related prote

30 after a delay of around 4 months, protecting antibodies against the short L1 appeared, enabling the v

31 n recognized by a broadly neutralizing human antibody against a broad range of H3N2 with high potency

32 We examined the prevalence of measles antibody among 12 349 newly hired HCP between 2009 and 2

33 The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a gro

34 2 of 10 (20%) relapses in patients with MOG antibodies and 12 of 13 (92.5%) with AQP4 antibodies (p

35 t comprises only the variable regions of the antibodies and a central bi-directional promoter.

36 Serum RSV-neutralizing antibodies and anti-RSV fusion immunoglobulin G increase

37 e, orthogonal and adaptable to different IgG antibodies and can be employed to achieve the targeted s

38 hese studies identify promising prophylactic antibodies and define protective epitopes that can be us

39 Monoclonal antibodies and hyperimmune globulin may provide addition

40 ignificantly reduced both class I and II HLA antibodies and increased the likelihood of identifying a

41 n immunocomplex was formed between anti-CD20 antibodies and lymphoma cancer cell receptors.

42 e semen significantly reduces the potency of antibodies and microbicides that target glycans on the e

43 elles that enables them to evade circulating antibodies and might affect tissue tropism.

44 analyses of antibodies, including bispecific antibodies and potential mispaired side products, in cel

45 evelopment and selection of humanized animal antibodies and provide actionable information for use in

46 A antigens synergize with HLA donor-specific antibodies and significantly increase the odds of reject

47 protein (Env) is the target of neutralizing antibodies and the template for vaccine immunogen design

48 layed significantly decreased donor-specific antibodies and, on prolonged treatment, modulated reject

49 on between a trans-cyclooctene (TCO)-bearing antibody and a tetrazine (Tz)-based radioligand via the

50 ccination than after the fourth, with higher antibody and cellular response rates at month 18 than at

51 haracterized by lack of parvalbumin-specific antibody and cellular responses.

52 E leads to the development of both anti-ZIKV antibody and T-cell responses in C57BL/6 mice.

53 lycan profile of a biotherapeutic monoclonal antibody and was able to achieve sensitive glycan identi

54 g specificities of lectins, anti-ganglioside antibodies, and serum antibodies of GBS patients.

55 were reactive by the Abbott IgG, Roche total antibody, and Abbott IgM assays, respectively, with samp

56 p = 0.001 for sacituzumab govitecan vs naked antibody, and sacituzumab govitecan vs control-ADC, resp

57 not compromise the affinity of the parental antibody, and utilizes chemically stabilized siRNA.

58 loyed to assess anti-human leukocyte antigen antibodies (Anti-HLA Ab) for donor-recipient matching an

59 ions, tumor cell doubling time, administered antibody, antibody specific-activity, and antigen-site d

60 The kinetics of antibody-antigen association are enhanced when charge re

61 urrently still only one therapeutic anti-IgE antibody approved for the treatment of allergic conditio

62 The target binding properties of antibodies are critical for their efficacy and toxicity.

63 Antibodies are key immune effectors that confer protecti

64 Several of these monoclonal antibodies are promising candidates for clinical develop

65 Antibodies are widely used as cancer therapeutics, but t

66 r findings reinforce the power of monoclonal antibodies as tools to interrogate structure-function re

67 to the poor sensitivity of immunofluorescent-antibody assays (IFAs), a reliable serodiagnostic test f

68 mation of the RBD on the spike and relies on antibody avidity for neutralization.

69 ntry and can guide future vaccine design and antibody-based drug therapy.

70 Antibody-based drugs and vaccines against severe acute r

71 Unlike the traditional antibody-based immunoassays, our approach is capable of

72 The key challenge in generating antibody-based inhibitors is the lack of fundamental inf

73 Bevacizumab was chosen as the antibody-based therapeutic.

74 -IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical

75 Cox proportional hazard model, HLA class II antibodies before transplantation were associated with i

76 a rhodamine and 153 kDa anti-VEGF monoclonal antibody (bevacizumab) upon IA injection.

77 Of 44 selected antibodies binding AAV2, AAV6 or AAV9, none exhibited ap

78 mory effect, changes of NH protection during antibody binding are measured.

79 cess, careful structural analysis beyond the antibody binding site is required to develop a more effi

80 We compared plasma antibody binding to HIV antigens between 51 nontransmitt

81 a new N-glycosylation site and mask it from antibody binding.

82 infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus

83 vident in the sera of the MS cohort, and the antibodies bound a heterogeneous set of molecules, inclu

84 ural changes for parent and affinity-matured antibodies bound to ARG2, with a large reorientation of

85 total IgG, IgG3 and IgG4, and donor-specific antibody by Luminex assay.

86 However, such antibodies can be expensive to produce, challenging to e

87 Levels of anti-DNA antibodies can fluctuate widely, unlike those of anti-RB

88 lement-dependent cytotoxicity panel reactive antibody [CDC PRA+], C1q+) heart transplant candidates w

89 mparative characterization of the monoclonal antibody Cetuximab.

90 3.7 angstrom resolution, with the aid of an antibody chaperone acting as a fiducial marker.

91 spike protein receptor binding domain total antibody chemiluminescence assay (100% sensitivity, 99.8

92 IgE is the least abundant circulating antibody class but is constitutively present in healthy

93 hly variable, differing in their format, the antibody class detected, the targeted antigen, and the a

94 ically relevant impact of IVIg on monoclonal antibody clearance and indirectly hint at an IVIg mechan

95 re prevalent in participants with SARS-CoV-2 antibodies, compared with those without antibodies (93.4

96 Antihuman lymphocyte serum (L1S1) antibody completely prevented acute GVHD.

97 t arm (10 mg/kg, providing therapeutic-level antibody concentrations), immediately followed by approx

98 epsin B or papain to release and measure the antibody-conjugated drug (acDrug) concentration.

99 d 100% specificity in identifying B. microti antibody containing sera in an ELISA.

100 These antibodies could predict prognosis or be potential inter

101 Two potently neutralizing monoclonal antibodies, COV2-2196 and COV2-2130, which recognize non

102 highly sensitized (calculated panel reactive antibody [cPRA] class I and/or II >99%, complement-depen

103 d with samples of anti-SARS-CoV-2 monoclonal antibody CR3022 (0.1 mug/ml, 1.0 mug/ml, 10 mug/ml).

104 non-immunized library of human single-domain antibodies (dAbs).

105 multiple myeloma (MM) include the anti-CD38 antibody daratumumab, which, in addition to its inherent

106 Immunotherapy with anti-CD38 monoclonal antibody (daratumumab) was proposed with a clinical and

107 r is a reliable approach to simplify complex antibody data and an ideal endpoint for desensitization

108 sensitization by accelerating pathogenic IgG antibody degradation.

109 ural killer (NK) cells resulting in crippled antibody-dependent cellular cytotoxicity (ADCC).

110 diminished natural cytotoxicity but enhanced antibody-dependent cellular cytotoxicity (ADCC).

111 PPD-specific isotype/subclass, PPD-specific antibody-dependent phagocytosis, cellular cytotoxicity,

112 o providing guidance for vaccine design, the antibodies described here are promising candidates for C

113 Early diagnosis of an infection based on antibody detection might lead to less invasive, early in

114 Env trimer immunization elicits neutralizing antibody development and production of antibodies facili

115 s)IgA, esIgE, esIgD, esIgG(1) , and esIgG(4) antibodies directed at 58 (15-mer) overlapping peptides,

116 mics to significantly streamline therapeutic antibody discovery.

117 ding to LL37, which correlate with anti-LL37 antibodies/disease activity.

118 protection has been defined to be primarily antibody driven.

119 Antibody drug conjugates (ADCs), which harness the high

120 spiking in known amounts of HCPs to purified antibody drug substance with low levels of HCPs, we demo

121 the selective cleavage of a tetrazine-linked antibody-drug conjugate by trans-cyclooctenes, affording

122 n both the heavy and light chains of a model antibody-drug conjugate, and calculation of the overall

123 Complex biotherapeutic modalities, such as antibody-drug conjugates (ADC), present significant chal

124 Antibody-Drug Conjugates (ADCs) developed as a targeted

125 alyze their relationship with donor-specific antibodies (DSA) and histological phenotype.

126 Reduction in donor-specific antibody (DSA) has been associated with improved renal a

127 Dynamic charge shifting within the antibody during its interaction with the antigen is enab

128 However, its effects on stimulating antibody effector functions, including NK cell activatio

129 onset, immunoglobulin (Ig) M, IgA, and total antibody ELISAs increased in sensitivity to >80% between

130 ar antibody scaffolds, trastuzumab, used for antibody engineering and drug conjugation.

131 Vaccine-induced antibodies exhibit a high degree of clonal diversity, re

132 , were down-regulated as cellular demand for antibody expression increased in CHO cells during the pr

133 izing antibody development and production of antibodies facilitating uptake of immunogens by antigen-

134 In conclusion, development of functional antibodies follows survival of acute EVD.

135 engineering of anti-influenza IgG monoclonal antibodies for selective binding to the activating Fcgam

136 Attempts to use antibodies for siRNA delivery have been reported but the

137 evels only in dAP7 cells and synergized with antibody for RNA clearance and improved cell survival.

138 The aim was to demonstrate that antibodies from patients with anti-N-methyl-d-aspartate

139 In this study, we isolated a single-chain antibody from an Indian dromedary camel (ICab) immunized

140 ed from the immunized camel and purified the antibody from Escherichia coli after refolding it from i

141 however, it is unclear how these protective antibodies function.

142 NMT inhibitors with anti-TIGIT or anti-KLRG1 antibodies further reduced metastatic potential.

143 Recently, the relevance of non-HLA antibodies has become more prominent as AMR can be diagn

144 Although neutralizing antibodies have been proposed as a potential key mechani

145 nter-residue distances and orientations from antibody heavy and light chain sequence.

146 o infect individuals with naturally acquired antibodies highly blocking the binding of PvDBP to the D

147 munized with recombinant LJM17 produced IgG1 antibodies (human IgG4 homolog) that strongly cross-reac

148 Antibody (IgG, IgG3 binding, and neutralizing) and CD4+

149 hermal unfolding of a recombinant monoclonal antibody IgG1 (mAb) was measured with differential scann

150 emplar, whereby CTLA4 activity is blocked by antibodies in cancer immunotherapy and augmented by the

151 sid antigen specifically captures SARS-CoV-2 antibodies in patient specimens.

152 This study reveals complex roles of antibodies in viral entry and can guide future vaccine d

153 tially injected intravenously with unlabeled antibody in a peripheral vessel in the right arm (10 mg/

154 rom Staphylococcus aureus We identified this antibody in a yeast display screen built from mononuclea

155 e concentration between HCPs and therapeutic antibody in solution, which precludes the effective iden

156 plus pembrolizumab (an anti-PD-1 monoclonal antibody) in previously treated patients with HER2-posit

157 platform affords high-throughput analyses of antibodies, including bispecific antibodies and potentia

158 The EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovas

159 ximately 40 MBq of one of the (89)Zr-labeled antibodies injected intravenously in a peripheral vessel

160 Antibody injection improved glucose tolerance in D734A I

161 ertheless, the development of biotherapeutic antibodies is complex, expensive, and time-consuming, an

162 The induction of anti-CSP antibodies is important for protection, however, it is u

163 hmatic sputum and targeting Siglec-8 with an antibody is a plausible strategy to decrease sputum eosi

164 Since SMI-32 antibody is considered to be a putative marker for Y cel

165 ongly correlate with the total anti-PLA(2)R1 antibody level (Spearman's rho, 0.95, 0.64, and 0.40; P<

166 antibody responses correlated strongly with antibody levels measured by ELISA (R(2)=0.67 by Marburg

167 d ELISA showed that domain-specific PLA(2)R1 antibody levels targeting CysR, CTLD1, and CTLD7 strongl

168 d subjects, and a wide range of serum/plasma antibody levels was delineated in infected subjects.

169 outcome independently of total anti-PLA(2)R1 antibody levels.

170 Previous M2e-specific monoclonal antibodies (M2e-MAbs) show protective potential against

171 the high targeting specificity of monoclonal antibodies (mAb) with the potency of small molecule ther

172 Here, we developed an anti-AQP3 monoclonal antibody (mAb) that inhibited AQP3-facilitated H(2)O(2)

173 By analyzing more than 500 monoclonal antibodies (mAbs) derived from B cells induced by numero

174 Although therapeutic monoclonal antibodies (mAbs) have demonstrated significant clinical

175 ity correlating directly with virus-specific antibody magnitude.

176 It correlated with tubulitis, arteritis, and antibody markers within concurrent histology (P < 0.001)

177 n test (RFFIT) for rabies virus neutralising antibody measurement.

178 of protection against many viral pathogens, antibodies mediate additional immune functions that may

179 expression at the cell surface may determine antibody-mediated cell death.

180 IV-1 infectivity and sensitizes the virus to antibody-mediated neutralization.

181 with improved renal allograft survival after antibody-mediated rejection (AMR).

182 hanisms by which the early synergism between antibody-mediated toxin neutralization and tissue-specif

183 ps, leukocyte homing was blocked by integrin antibodies (n = 5).

184 ped SARS-CoV-2-specific immunoglobulin (IgG) antibodies, neutralizing plasma, and memory B and memory

185 cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibod

186 tins, anti-ganglioside antibodies, and serum antibodies of GBS patients.

187 roduce a method for a related task: given an antibody of interest and its inferred ancestral lineage,

188 shing steps that desorbs the capture antigen/antibody off the polystyrene plate, thereby producing in

189 mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-mug dose) to 3.5-f

190 Of these 8 antibodies, only 5 ameliorated ITP.

191 ors in vitro after exposure to patients' CSF antibodies or SSM5, we used a functional assay based on

192 Targeting MARCO or IL37 receptor (IL37R) by antibody or CRISPR knockout of IL37 in lung cancer cell

193 assay format without the need of a secondary antibody, or washing steps.

194 Antibody- or shRNA-mediated functional ABCB5 blockade in

195 OG antibodies and 12 of 13 (92.5%) with AQP4 antibodies (p < 0.001).

196 ull cells treated with an ERBB3-neutralizing antibody partially downregulated mTOR pathway activation

197 ility of research findings, and inconsistent antibody performance leads to variability in Western blo

198 During acute illness, antibodies predominate to VP40 and glycoprotein (GP).

199 tive identification of low abundance HCPs in antibody product.

200 this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a lar

201 As such, we compared the antibody profile to HA and NA in two naturally infected

202 Passively acquired maternal GBS-specific antibodies protect newborns from early-onset disease, ye

203 ory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection r

204 n disulfide bonds and has an average drug to antibody ratio (DAR) of 2.

205 Anti-CNS antibody reactivity was evident in the sera of the MS co

206 Well-characterized antibody reagents play a key role in the reproducibility

207 This result has implications for antibody recognition of MPER prior to and during the pro

208 f anti-PD-1 inhibitory and anti-OX40 agonist antibodies reduces the proportion of T-regulatory and ex

209 ble, the functional characterization of such antibodies represents a powerful tool for the developmen

210 " viruses significantly enhances the anti-NA antibody response compared to vaccination with unmodifie

211 Neutralising antibody responses against SARS-CoV-2 were detected in 3

212 and their vaccine efficacy (antigen-specific antibody responses and IFN-gamma production) and biodist

213 g rare B cells capable of broadly protective antibody responses are not hindered by promotion of term

214 induction of functionally active polyclonal antibody responses as measured in the standard membrane

215 Neutralising antibody responses correlated strongly with antibody lev

216 In addition to neutralizing IgG antibody responses in a protective range, multifunctiona

217 Here, we show distinct antibody responses in children and adults after SARS-CoV

218 In this study we compared the antibody responses in humans after vaccination with an A

219 w that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mu

220 Antibody responses to SARS-CoV-2 are unimodally distribu

221 IV-1 vaccine-induced antienvelope (anti-Env) antibody responses.

222 ell responses correlated with spike-specific antibody responses.

223 ccination requires elicitation of long-lived antibody responses.

224 Neutralizing antibodies rose in tandem with immunoglobulin titers fol

225 thionines throughout one of the most popular antibody scaffolds, trastuzumab, used for antibody engin

226 nting instrumentation and will be useful for antibody screening, custom assay development, biomarker

227 tence of Vi-specific IgG in serum and IgG(+) antibody-secreting cells in bone marrow.

228 We develop a pipeline, Antibody Sequence Analysis Pipeline using Statistical te

229 We identify convergence of antibody sequences across SARS-CoV-2-infected patients,

230 dentify features that distinguish one set of antibody sequences from antibody sequences in a referenc

231 stinguish one set of antibody sequences from antibody sequences in a reference set.

232 RS-CoV-2-specific T cells were detectable in antibody-seronegative exposed family members and convale

233 We demonstrate that using cGMP-specific antibody, sGC or PDE activity and the effect of small mo

234 The antibodies shift the voltage dependence of activation an

235 Here, we report a method to generate antibody-siRNA (1:2) conjugates (ARCs) that are structur

236 typically stimulate the production of potent antibodies specific for the pathogen through a Darwinian

237 r cell doubling time, administered antibody, antibody specific-activity, and antigen-site density mos

238 Baseline antibody status was determined by anti-spike (primary an

239 n not observed in previously described RSV G-antibody structures.

240 ic (CD14) but not CD4+ T cell-specific (CD3) antibodies, suggesting that M-tropic viruses had a macro

241 more, clinically approved PCSK9-neutralizing antibodies synergize with anti-PD1 therapy in suppressin

242 that nascent plasma cells adapt to increased antibody synthesis by activating the unfolded protein re

243 The negative depletion of antibody-tagged leukocytes enables isolation of potentia

244 ls who were seronegative for anti-SARS-CoV-2 antibodies targeting spike (S) and nucleoprotein (N).

245 Antibodies targeting the RSV G central conserved domain

246 ynamics (PD) of the human anti-C5 monoclonal antibody tesidolumab (LFG316) in end-stage renal disease

247 bodies of different isotypes, and the use of antibody testing in identification of acutely ill patien

248 t neutralization by a panel of gB monoclonal antibodies than a wild-type gC rescuant virus.

249 oduce high quantities of the glycan-specific antibodies that can be protective against infectious age

250 We found that all of the antibodies that cause shorter FLS interact with SNX9, an

251 We find that this vaccine strain elicits antibodies that have reduced reactivity to a wild-type 3

252 platform for the detection of IgG anti-drug antibodies that may provide an initial screen for all th

253 combination of antigen- and epitope-specific antibodies that using 3- to 15-month or 2- to 3-year sam

254 ere, we stabilize immature Zika virus via an antibody that binds across the E and prM proteins, resul

255 AK002 (lirentelimab) is an anti-Siglec-8 antibody that depletes eosinophils and inhibits mast cel

256 that a patient with VZV CNS vasculopathy had antibody that neutralized interferon (IFN)-alpha, but no

257 Daratumumab is a monoclonal antibody that targets CD38, an antigen expressed on near

258 are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible

259 ion and analyzed in relation to preinfection antibody titer (measured by inhibition enzyme-linked imm

260 not all recovered patients develop adequate antibody titers for donation and the relationship betwee

261 erpesvirus (KSHV) DNA in blood and increased antibody titres may indicate KSHV reactivation, while th

262 Seasonal IIV could not induce seroprotective antibodies to 2010.1 cluster A(H3N2)v viruses in young c

263 Antibodies to 4/18 non-HLA antigens synergize with HLA d

264 le of the microbiota in eliciting protective antibodies to a specific neonatal pathogen represents an

265 sitive (99%) and specific (93%) detection of antibodies to all FMDV strains used in this study.

266 based assay for the detection of IgM and IgG antibodies to B. burgdorferi The BioPlex 2200 Lyme Total

267 was collected from each child and tested for antibodies to C. trachomatis.

268 We used cell-specific monoclonal antibodies to eliminate neutrophils, monocytes, or both.

269 ative antigen for vaccine development, since antibodies to NS1 do not bind to the virion, thereby eli

270 d 4 of 21 (19.0%) placebo controls developed antibodies to PfCSP (P < .001).

271 e, patterns of, and factors associated with, antibodies to RVF virus (RVFV) in livestock in an area h

272 Antibodies to SARS-CoV-2 predicted the odds of developin

273 eflectometry (AIR) platform for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circul

274 on the principle that binding of monoclonal antibodies to specific epitopes of T. b.

275 s by cross-linking pMHC or using multivalent antibodies to TCR.

276 Injection of inhibitory antibodies to the alpha subunit of the Gs heterodimeric

277 ) assays, we characterized IgG, IgM, and IgA antibodies to the spike receptor binding domain (RBD), S

278 undamental information relating sequences of antibodies to their unique properties as inhibitors.

279 antation, the presence of naturally-existing antibodies to TKO pig cells in OWMs complicates the tran

280 n experimental studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uP

281 munity [thyroid peroxidase and thyroglobulin antibodies (TPOAb and TgAb, respectively)] in serum usin

282 In addition to labeling the monoclonal antibody trastuzumab with excellent cysteine-selectivity

283 The association with DQ antibody-verified eplet mismatches was linear, without a

284 The quantification of antibody-verified eplets (VerEp) mismatch was performed

285 ) is essential in the induction of anti-RABV antibodies via the facilitation of germinal center forma

286 in combination with the broadly neutralizing antibody VRC01-N using a highly reproducible humanized m

287 IgG over the fold-rise in RSV-A-neutralizing antibodies was 1.01.

288 A subset of the antibodies was able to potently inhibit authentic SARS-C

289 ping showed that this collection of nineteen antibodies was about equally divided between those direc

290 oglobulin G (IgG) and immunoglobulin M (IgM) antibodies was undertaken under medical supervision.

291 SARS-CoV-2, and fewer than 10% of those with antibodies were diagnosed.

292 ss-reacted with recombinant DSG1; these IgG1 antibodies were inhibited by LJM17, LJM11, and DSG1 in a

293 osted regimens, half-lives of gp120-specific antibodies were longer but peak magnitudes were lower in

294 Serum toxin A- and B-specific neutralizing antibodies were measured.

295 ements of anti-N-methyl-D-aspartate receptor antibodies were taken in 49 (14%) patients.

296 rrently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse e

297 n fluctuate widely, unlike those of anti-RBP antibodies, which tend to be stable.

298 onse without eliciting significant anti-ZIKV antibodies, while vaccination with Ad5-prM-E leads to th

299 ax, the RBD derivative elicited neutralizing antibodies with an endpoint geometric mean titer of ~415

300 mer peptide and found that it binds the scFv antibody with a K(D) (equilibrium dissociation constant)